Skip to main
BLCO

BLCO Stock Forecast & Price Target

BLCO Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 31%
Hold 46%
Sell 0%
Strong Sell 0%

Bulls say

Bausch & Lomb is well-positioned for growth and profitability due to its restructuring efforts and strong management team. However, potential underperformance in contact lens sales could impact revenue projections. The company's product pipeline and focus on developing new medical devices and treatments should drive future growth, and positive results for existing medical assets have boosted investor confidence. With a solid portfolio and a favorable outlook in the eye care market, B&L has the potential to deliver strong returns for investors.

Bears say

Bausch & Lomb is facing headwinds in the form of weakening demand for its over-the-counter medications and increased competition in the contact lens market. Additionally, their flagship dry eye treatment, RESTASIS, has limitations in terms of delayed onset of action and potential side effects. Despite growth in the premium lens market, the company's overall growth may be hindered by these factors. The company's leadership has a strong background in the healthcare industry, but the return of former CEO Brent Saunders may signal a focus on corporate transactions over long-term growth. Investors should carefully consider these factors before investing in Bausch & Lomb's stock.

BLCO has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 31% recommend Buy, 46% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bausch + Lomb Corp (BLCO) Forecast

Analysts have given BLCO a Buy based on their latest research and market trends.

According to 13 analysts, BLCO has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bausch + Lomb Corp (BLCO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.